Robert Charles Doebele
University of Colorado Cancer Center · 532 works · 31,913 citations · h-index 74
Top works
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- Treating ALK-positive lung cancer—early successes and future challenges
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers